Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14507
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chittasupho C. | |
dc.contributor.author | Siahaan T.J. | |
dc.contributor.author | Vines C.M. | |
dc.contributor.author | Berkland C. | |
dc.date.accessioned | 2021-04-05T03:35:14Z | - |
dc.date.available | 2021-04-05T03:35:14Z | - |
dc.date.issued | 2011 | |
dc.identifier.issn | 20415990 | |
dc.identifier.other | 2-s2.0-79961177838 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14507 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79961177838&doi=10.4155%2ftde.11.60&partnerID=40&md5=34201a5607326ab185a08e4094899c9d | |
dc.description.abstract | Proteins participating in immunological signaling have emerged as important targets for controlling the immune response. A multitude of receptor-ligand pairs that regulate signaling pathways of the immune response have been identified. In the complex milieu of immune signaling, therapeutic agents targeting mediators of cellular signaling often either activate an inflammatory immune response or induce tolerance. This review is primarily focused on therapeutics that inhibit the inflammatory immune response by targeting membrane-bound proteins regulating costimulation or mediating immune-cell adhesion. Many of these signals participate in larger, organized structures such as the immunological synapse. Receptor clustering and arrangement into organized structures is also reviewed and emerging trends implicating a potential role for multivalent therapeutics is posited. © 2011 Future Science Ltd. | |
dc.subject | abatacept | |
dc.subject | adalimumab | |
dc.subject | autoantibody | |
dc.subject | B7 antigen | |
dc.subject | belatacept | |
dc.subject | CD28 antigen | |
dc.subject | cholinergic receptor | |
dc.subject | corticosteroid derivative | |
dc.subject | cytokine | |
dc.subject | cytotoxic agent | |
dc.subject | cytotoxic T lymphocyte antigen 4 | |
dc.subject | dacetuzumab | |
dc.subject | efalizumab | |
dc.subject | etanercept | |
dc.subject | galiximab | |
dc.subject | immunoglobulin | |
dc.subject | infliximab | |
dc.subject | intercellular adhesion molecule 1 | |
dc.subject | intercellular adhesion molecule 1 antibody | |
dc.subject | ipilimumab | |
dc.subject | lymphocyte function associated antigen 1 | |
dc.subject | major histocompatibility antigen class 2 | |
dc.subject | membrane protein | |
dc.subject | methotrexate | |
dc.subject | natalizumab | |
dc.subject | programmed death 1 receptor | |
dc.subject | rituximab | |
dc.subject | thyrotropin receptor | |
dc.subject | ticilimumab | |
dc.subject | unindexed drug | |
dc.subject | antigen presenting cell | |
dc.subject | autoimmune disease | |
dc.subject | autoimmunity | |
dc.subject | B cell lymphoma | |
dc.subject | brain infection | |
dc.subject | brain ischemia | |
dc.subject | cell adhesion | |
dc.subject | cellular immunity | |
dc.subject | chronic lymphatic leukemia | |
dc.subject | Crohn disease | |
dc.subject | cytokine production | |
dc.subject | drug protein binding | |
dc.subject | drug receptor binding | |
dc.subject | drug targeting | |
dc.subject | drug withdrawal | |
dc.subject | human | |
dc.subject | immunological synapse | |
dc.subject | immunoregulation | |
dc.subject | immunostimulation | |
dc.subject | lymphocyte proliferation | |
dc.subject | melanoma | |
dc.subject | multiple myeloma | |
dc.subject | multiple sclerosis | |
dc.subject | nonhodgkin lymphoma | |
dc.subject | nonhuman | |
dc.subject | phase 1 clinical trial (topic) | |
dc.subject | phase 2 clinical trial (topic) | |
dc.subject | phase 3 clinical trial (topic) | |
dc.subject | priority journal | |
dc.subject | progressive multifocal leukoencephalopathy | |
dc.subject | psoriasis | |
dc.subject | review | |
dc.subject | rheumatoid arthritis | |
dc.subject | signal transduction | |
dc.subject | T lymphocyte activation | |
dc.subject | Animals | |
dc.subject | Autoimmune Diseases | |
dc.subject | Cell Adhesion | |
dc.subject | Drug Delivery Systems | |
dc.subject | Humans | |
dc.subject | Immune Tolerance | |
dc.subject | Immunological Synapses | |
dc.subject | Inflammation | |
dc.subject | Proteins | |
dc.subject | Signal Transduction | |
dc.title | Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics | |
dc.type | Review | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Therapeutic Delivery. Vol 2, No.7 (2011), p.873-889 | |
dc.identifier.doi | 10.4155/tde.11.60 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.